Treatment News : Sofosbuvir, Daclatasvir Combo Cures 100% in Hep C Trial

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 29, 2013

Sofosbuvir, Daclatasvir Combo Cures 100% in Hep C Trial

Gilead Sciences’ sofosbuvir and Bristol-Myers Squibb’s daclatasvir, taken with or without ribavirin, cured 100 percent of previously treated participants of hepatitis C virus (HCV) in a recent trial, echoing previous studies of this highly potent combination therapy, Bloomberg Businessweek reports. However, because of the fact that Gilead has opted not to work jointly with BMS on advanced studies of the two drugs in combination, preferring instead to set its sights on a single combination pill of sofosbuvir with the company’s own ledipasvir, it appears unlikely there will ever be a U.S. Food and Drug Administration approval of sofosbuvir and daclatasvir in combination.

The results of the study, which included 41 people with genotype 1 of hep C who had failed an interferon-based therapy including either Victrelis (boceprevir) or Incivek (telaprevir), were presented at the International Liver Congress, the 48th annual meeting of the European Association for the Study of the Liver (EASL) in Amsterdam.

The study did not include those with cirrhosis of the liver, although more than four in five of the participants had moderate fibrosis or higher.

The participants were randomly assigned to receive the NS5A replication complex inhibitor daclatasvir and the nucleotide analog HCV polymerase inhibitor sofosbuvir either with or without ribavirin for 24 weeks.

All 41 of the participants achieved a sustained virologic response (SVR, considered a cure) 24 weeks after completing the therapy. The treatment was generally safe and well tolerated in both arms of the study. Those taking ribavirin reported greater fatigue and gastrointestinal symptoms.

If both drugs are approved as independent agents, physicians will have the option to prescribe them “off-label.”

To read the Bloomberg story, click here.

To read the abstract and see study slides, click here.

Search: Gilead Sciences, sofosbuvir, Bristol-Myers Squibb, daclatasvir, hepatitis C virus, HCV, hep C, Bloomberg Businessweek, U.S. Food and Drug Administration, Victrelis, boceprivir, Incivek, telaprevir, 48th annual meeting of the European Association for the Study of the Liver, EASL.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 3 (of 3 total)    

mike wurm, pensacola, 2014-08-14 04:27:49
about five years ago I began the ribavarin/interferon injections. went about 6 months and was dropped from the study with no comments or follow-up.so how do go about locating and receiving these new drugs? please help!!!!!

Death Sentence, , 2014-02-03 11:55:24
So a promising 100% cure is dangled before HepC sufferers only to be dashed by greedy pharma, government agencies that won't regulate and insurance companies that refuse to insure which, will lead to death sentences for many. For-profit healthcare advocates in the United States should hang their collective heads in shame. The large pension managers should put forth divestment strategies of all Gilead & Bristol holdings since, their baby-boomer cliental are 5-times more likely to be affected.

gregory broome, lexington s.c.29072, 2014-01-18 21:15:12
i have hepc and meld factor 10 transplant list but no insurance or medicaid this drug combo would be a blessing fromGOD!!!!wish i could get in on clinical studies!!!

comments 1 - 3 (of 3 total)    


[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    acousticmat
    Tucson
    Arizona


    romanticseattle
    Tacoma
    Washington


    usuallyhappy
    Palm Springs
    California


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.